arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

CEL SCI CORP

CVM
$1.35 ▼ -0.06 (-4.26%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

CEL SCI CORP faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC -40.1% ↗
FCF / Share None
Trailing P/E —
Price / Book 2.2x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$77.40K
↑ +150.5% —
Net Income Profit after all expenses
$-5.47M
↑ +22.7% —
FCF / Share Free cash flow per share
$-0.11
↑ +2.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
4
Financial Health ↓
19
Cash Quality ↓
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 68 quarters